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Abstract: 
When advanced prostate cancer recurred during hormonal therapy and 
became the castration-resistant prostate cancer (CRPC), “vintage hormonal 
therapy” such as antiandrogen alternating therapy or estrogen-related 
hormonal therapy was widely conducted in Japan until 2013. This vintage 
hormonal therapy controlled the progression of CRPC. When CRPC relapses 
during these therapies, chemotherapy using docetaxel has been conducted 
subsequently. Since new hormonal therapies using abiraterone acetate and 
enzalutamide which improve the prognosis of CRPC have been available in 
Japan from 2014, therapeutic options for CRPC increased. Moreover, the 
improvement of the further prognosis is promising by using cabazitaxel for 
docetaxel-resistant CRPC and radium-223 for CRPC with bone metastasis. 
Increase in therapeutic options gives rise to many questions including best 
timing to use them and the indication. Furthermore, physicians have to 
consider the treatment for the recurrence after having conducted 
chemotherapy. We want to argue the difference in hormonal therapy 
between Japan and western countries and problems when conducting new 
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The initial treatment for advanced prostate cancer is mainly hormonal therapy. 
However, the treatment strategy is different between Japan and in western countries. Many 
physicians in western countries do not recommend combined androgen blockade (CAB) i.e., 
the combined use of castration and an antiandrogen 
1
. Although addition of antiandrogen to 
castration for advanced prostate cancer may produce improvement of about 2% or 3% in 
overall survival, it does not produce great benefit for patients 
2
. This may be one of the 
reasons why they prefer castration only. In contrast, advanced prostate cancer is treated with 
CAB at many institutions in Japan. At least until the first half of 2014, various forms of 
hormonal therapy (so-called vintage hormonal therapy) have been performed on cases of 
prostate cancer that have advanced to castration-resistant prostate cancer (CRPC) 
3-5
. 
Dexamethasone also has favorable effects on CRPC 
6
. Chemotherapy using docetaxel has 
become available for recurrence after these vintage hormonal therapies in Japan since 2008 
7
. 
And best supportive care (BSC) has been chosen once efficacy of docetaxel is lost.  
Since 2014, novel drugs for hormonal therapy (enzalutamide and abiraterone) and 
chemotherapy (cabazitaxel) have been added to the coverage of the national health insurance 




system in Japan, and therapeutic approaches to CRPC have changed. Radium-223, a 
therapeutic agent for bone metastases of CRPC, has also been made available for clinical use 
in 2016.  
It is sometime difficult to choose vintage hormonal therapy and new drugs for 
CRPC. We argue the difference in management of hormonal therapies between Japan and in 
western countries and how to use new drugs in this review article. 
 
Vintage hormonal therapy 
 The usefulness of CAB for advanced prostate cancer has been demonstrated for 
stage C and D1 cases in a prospective clinical study conducted in Japan, except D2 case 
8
. In 
reality, however, there are many institutions in Japan that use CAB. CAB has been proven 
useful also for stage D2 cases through an analysis using the J-CaP database, although it was a 
retrospective study 
9
. A possible reason why CAB is not very useful in western countries is 
that a lower bicalutamide dose of 50 mg/day is used in western countries, while the dose in 
Japan is 80 mg/day. It was clear that the higher dose of bicalutamide (100 mg/day or 150 
mg/day) was more effective 
10
. Therefore, it is potentially insufficient for 50 mg/day 
bicalutamide to exert the adequate antiandrogen effect. For CRPC occurring after CAB, it 




was common in Japan to confirm the antiandrogen withdrawal effect 
11
 or perform alternative 
antiandrogen therapy 
3
. In particular, it has been shown that alternative antiandrogen therapy 
decreased prostate specific antigen (PSA) in 60–80% of patients, and that decreased PSA was 
associated with good prognosis 
3, 12
. After these reports on the usefulness of alternative 
antiandrogen therapy, this therapy has been commonly used in Japan. In addition, 
estrogen-related drugs, such as estramustine phosphate and ethinyl-estradiol, have also been 
used for post recurrence of alternative antiandrogen therapy. In particular, the usefulness of 
ethinyl-estradiol has been assessed in retrospective studies, and favorable results have been 
obtained, demonstrating PSA progression f ee survival (PFS) of 10 months in CRPC patients 
in Japan and PFS of 15.1 months in metastatic CRPC in western countries 
4, 13
. 
Administration of low-dose estramustine phosphate for CRPC showed favorable response 
before docetaxel treatment (7.1-month median PFS, and 42-month overall survival in 31 
patients with CPRC) 
5
. Also for dexamethasone, which has been used extensively for CRPC 
in Japan because of benefit in treatment of CRPC 
14
, the usefulness has been reconfirmed by 
a prospective study in western countries comparing dexamethasone and prednisone for 
treatment of CRPC, in which PFS periods were 9.7 months and 5.1 months, respectively 
15
. 
In western countries, prospective clinical studies of hormonal therapy combined with 




docetaxel from the initial treatment for advanced prostate cancer (CHAARTED study & 
STAMPEDE study), compared to 44 months and 45 months in hormonal therapy alone 
groups, overall survival rates in docetaxel-hormonal therapy combination groups were 57.6 
months and 60 months, respectively 
16, 17
. Meanwhile, a retrospective study using the large 
J-CaP database (N = 5618) has reported overall survival rates of 80.4 months, 67.2 months, 
and 45.6 months for stages M1a (N = 224), M1b (N = 4386), and M1c (N = 278), 
respectively, while showing good survival even without docetaxel in the initial treatment 
9
. 
Although there may also be racial differences in responsiveness to hormonal therapy 
18
, good 
survival rates in Japan may be attributable in part to traditional treatments (vintage hormonal 
therapy) for CRPC including alternative antiandrogen therapy. 
 
New hormonal therapy 
Enzalutamide, a second-generation antiandrogen, and abiraterone acetate, an adrenal 
androgen synthesis inhibitor, were added to the coverage of the national health insurance 
system in Japan in 2014, and have been available for unrestricted clinical use for treatment of 
CRPC. These two drugs have been demonstrated to be useful for treatment of CRPC, whether 
or not docetaxel is used, in clinical studies conducted in Japan and in western countries 
19-25
. 




This paper briefly reviews the pathogenesis of CRPC and the mechanism of action of 
these two drugs against CRPC 
26
. Prostate cancer becomes CRPC mainly via two 
mechanisms. One is adaptation, in which prostate cancer cells gradually adapt to a 
post-castration low-androgen environment through reactivation of androgen receptor (AR) 
(hypersensitive AR). The other is clonal selection, in which androgen-independent prostate 
cancer (AIPC) cells, which exist more or less originally, increase after castration. Prognosis 
of CRPC is considered to differ depending on which of the two mechanisms has played a 
major role in CRPC development. In the case of Japan, given the aforementioned fact that 
certain therapeutic effects are produced by switching among antiandrogen agents 
3
, CRPC 
presumably develops mainly though adaptation according to the result of alternative 
antiandrogen therapy 
3
. More specifically, in a majority of prostate cancer cases that have 
advanced to CRPC, testosterone and DHT are considered to be synthesized from androgen of 




If hypersensitive AR can be inhibited more strongly, CRPC caused via adaptation is 
likely to be more effectively treatable. This is realized by the advent of the two new drugs for 
hormonal therapy. Enzalutamide shows about 8-times higher AR affinity than the 




first-generation antiandrogen bicalutamide 
28
. Furthermore, enzalutamide inhibits nuclear 
translocation of AR and also inhibits AR from binding to DNA by preventing the cofactor 
from binding to AR 
28
. Abiraterone, on the other hand, inhibits androgen (DHEA) synthesis in 
the testis, adrenal gland, and prostate cancer tissues, decreases intracellular androgen levels, 
and inhibits AR activation. It is easy to understand if it is put this way; enzalutamide inhibits 
the downstream of AR more strongly, whereas abiraterone potently inhibits the upstream of 
AR. Nevertheless, enzalutamide and abiraterone may be equally effective in the sense that 
they basically inhibit the AR axis signaling pathway more strongly than conventional 
antiandrogens. 
 
Indication of new hormonal therapies 
In view of the pathogenesis of CRPC and the mechanism of action of the novel hormonal 
therapy drugs, it may be effective to start using these drugs as soon as the disease becomes 
CRPC. However, about 60% of patients are expected to enjoy improvements in prognosis by 
reducing PSA with vintage hormonal therapy as the initial treatment against CRPC such as 
alternative antiandrogen therapy 
3
. In addition, when patient background was compared 
between in western countries and Japanese clinical studies using post-docetaxel abiraterone 




and enzalutamide, vintage hormonal therapy was noticeably more commonly used among 
patients enrolled in studies in Japan (Fig. 1) 
29
. The results from studies conducted in Japan 
showed the effectiveness of these drugs, although the efficacy of new hormone therapy 
agents was somewhat lower than that in in western countries studies 
23, 24
. Western countries 
study has also suggested that the efficacy of abiraterone does not change appreciably 
depending on whether diethylstilboestrol (DES) is used 
30
. Thus, if new drugs can be 
expected to be effective even after treatment with vintage hormonal therapy, is it necessary to 
use new drugs in a hurry? Rather, the final prognosis after CRPC may be improved by using 
new drugs after using vintage hormonal therapy. Conversely, if response and survival benefit 
can be expected from the use of vintage hormonal therapy, such as alternative antiandrogen 
therapy, after using potent new hormone therapy drugs, it may be also valid; however, 
unfortunately, this remains to be tested in clinical studies. It would be acceptable to use 
vintage hormonal therapy for 1 to 3 months and then decide whether to continue it or switch 
to some other treatment based on the change of PSA, and radiographic change, and symptom.  
Moreover, there are some points to be aware of if new hormonal therapy drugs are to be 
used early in CRPC. It is a problem of drug resistance occurring due to long-term use. One of 
mechanisms for abiraterone/enzalutamide resistance is expression of an AR splicing variant 








. Studies in cultured cell systems have shown induction of AR-V7 expression 
due to increased RNA editing factors (U1A, U2A) after complete removal of androgen or 
addition of enzalutamide 
33
, suggesting the possibility that long-term strong inhibition of AR 
activation leads to increased expression of AR-V7 and affects prognosis. 
Enzalutamide/abiraterone converted AR-V7 positive in patients whose AR-V7 was initially 
undetectable 
34
. Moreover, nuclear AR-V7 expression increased after 
enzalutamide/abiraterone in CRPC biopsy samples 
35
. Among metastatic CRPC patients who 
received abiraterone or enzalutamide, OS and PSA-PFS in those positive for AR-V7 
expression after the treatment have been reported to be significantly lower than in those with 
no expression 
34
. If these drugs are to be started at an early stage of CRPC, physicians should 
be aware of the possibility of AR-V7 induction, although emergence of AR-V7 may be 
involved in other mechanisms. 
 
Chemotherapy 
      Since the effectiveness of docetaxel against CRPC has been demonstrated 
36, 37
, 
docetaxel has become available for medical care under the national insurance system in Japan 
since 2008 
7
. While the maximum use of docetaxel is limited to 10 courses in western 




countries, there are no restrictions on this respect in Japan and more than 10 courses of 
docetaxel can be used for some patients 
38
. This may contribute to prolong prognosis for 
Japanese patients. However, long-term use of docetaxel in the standard regimen is not 
possible for many patients due to adverse effects, and biweekly administration of docetaxel 
has been reported to be effective and safe 
39
. With this method, quality of life (QOL) during 
treatment with docetaxel is expected to be improved without losing the effectiveness of 
docetaxel. 
      However, treatment becomes difficult once docetaxel resistance develops. One of 
mechanisms for resistance to docetaxel is increased expression of P-glycoprotein from 
multiple drug resistant gene 1 (MDR1) 
40
. P-glycoprotein is a cell membrane protein and has 
a function of extracellularly releasing docetaxel that has entered cells. Cabazitaxel is an 
anticancer agent effective against docetaxel-resistant prostate cancer 
41
. Since cabazitaxel has 
low affinity to P-glycoprotein, it is not captured by P-glycoprotein even when its expression 
is enhanced by docetaxel, and thus is not easily released outside of cancer cells. The 
effectiveness of cabazitaxel against docetaxel-resistant prostate cancer has also been 
demonstrated in Japan. Since cabazitaxel has low affinity to P-glycoprotein, which is 
considered responsible for blood brain barrier, cabazitaxel is expected to be effective against 






. However, it remains controversial as to when is the best to switch 
docetaxel to cabazitaxel. In other words, it is difficult to judge how long to continue 
docetaxel and when to switch to cabazitaxel while docetaxel is still effective. 
Recently reported results from CHAARTED and STAMPEDE trials have shown 
that overall survival was improved by using six courses of docetaxel from the initial 
androgen-deprivation therapy in prostate cancer patients with metastases 
16, 17
. This hormonal 
chemotherapy from the initial treatment is now being established as a standard treatment in 
western countries. Yet this treatment cannot be performed currently in Japan because of 
insurance restrictions. This treatment may become available for patients in Japan someday, 
but then the patient selection would be a problem. I have formulated a hypothesis about why 
this treatment is effective for advanced prostate cancer 
29
. This hormonal chemotherapy is 
thought to be useful for patients with high-level AIPC before treatment with low-AR 
expression. AIPC is speculated to be more in patients with a very high grade of malignancy 
44, 
45
. AR immunostaining with a pattern oriented approach for response was capable of 
accurately predicting response to hormone therapy in patients with advanced stage disease 
46
. 
Hormonal chemotherapy may be effective, if it is performed selectively on such patients with 
low-AR expression.  






Relapses after new hormonal therapy are treated with docetaxel or cabazitaxel, but 
for relapses after that, physicians would often perform BSC. However, new hormonal therapy 
rechallenge after chemotherapy can sometimes reduce PSA again and improve the situation. 
Onishi et al. described that ethinylestradiol rechallenge for CRPC lead to a prolonged disease 
control in selected patient 47. Abiraterone acetate rechallenge also decreased PSA in 
heavily pre-treated CRPC patients 48. We also observed the cases whose PSA was 
decreased by enzalutamide and abiraterone acetate after heavily pre-treatments 
including chemotherapy (Fig. 2). Although rechallenge is not applicable to all CRPC 
patients, hormonal therapy may be attempted before starting BSC. Similar phenomenon was 
observed in a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung 
cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain 49. 
They showed that clonal progression was related with resensitization to crizotinib against 
lorlatinib ALK Resistance Mutation L1198F 49. I formulated the following hypothesis as to 
why rechallenge is effective for CRPC after some hormonal therapies and chemotherapy (Fig. 
3). CRPC is in a situation where two clonal cell populations, hormone-hypersensitive prostate 




cancer (HHSPC) and AIPC, are mixed. New hormonal therapy, of course, is only effective 
for HHSPC cells. Docetaxel may inhibit the proliferation of HHSPC in some degree. In 
contrast, COU-AA-301 trial and AFFIRM trial revealed HHSPC can survive after docetaxel 
treatment because abiraterone and enzalutamide were still effective after docetaxel 
50, 51
. In 
other words, the effect of docetaxel is restrictive for HHSPC. On the other hands, new 
hormonal therapy decreases the number of HHSPC cells, but may be ineffective for AIPC. 
When chemotherapy is then performed, the number of AIPC cells decreases, but surviving 
HHSPC and stem cell-derived HSPC may increase again 
52, 53
. If new hormonal therapy is 
performed thereafter again, HHSPC cells decrease and AIPC cells increase again. Eventually, 
AIPC cells become resistant to all treatments finally, and kill the patient. Alternating 
hormonal therapy and chemotherapy in this way causes changes in the ratio of HHSPC and 
AIPC cells, an effect that seems like seesaw (Seesaw theory). In addition, it is thought that 
prostatic cancer progresses further through interactions between HSPC and AIPC (our 
unpublished data). The above-mentioned CHAARTED and STAMPEDE trials may be 
effective presumably because HSPC and AIPC are simultaneously attacked by hormone 
chemotherapy and thus this seesaw does not move. 
 




Border attack by Ra-223 
Japanese health insurance started to cover the treatment of Radium-223 (Ra-223) for CRPC 
with bone metastasis in 2016. According to ALSYMPCA trial using Ra-223, Ra-223, as 
compared with placebo, significantly improved overall survival (median, 14.0 months vs. 
11.2 months) 
54
. Moreover, time to first symptomatic skeletal event (SSE) was longer with 
Ra-223 than with placebo (median 15.6 months vs 9.8 months) 
55
. However, in Phase II study 
using Ra-223, a lot of cases that PSA was elevated were observed although Alp was 
decreased 
56
. Even in Phase II study in Japan using Ra-223, the mean change rate of PSA by 
Ra-223 was rather increased to 97.3% and 230.5% although the mean change rate of Alp was 
-19.3% and -1.9% on 12 weeks after first treatment and 4 weeks after final treatment, 
respectively. We experienced the case that PSA continued being elevated although 
bone-derived Alp (BAP) and Bone Scan Index (BSI) on bone scintigraphy were improved by 
Ra-223 
57, 58
. It remains unclear why such discrepancy occurs by Ra-223. A feature of Ra-223 
is to release alpha particle of which flying length is very short 
59
. This is the reason why 
incidence of myelosuppression caused by Ra-223 is low compared with Sr-89. However, a 
short flying length of alpha particle was considered with a problem. Previously we studied 
the repression of osteoplastic bone metastases of the prostate cancer by bisphosphonate in 






. We noticed that a lot of prostate caner cells still remained in bone marrow although 
bisphosphonate existing in the bone matrix could prevent cancer cells from infiltrating into a 
bone matrix at that time (Fig. 2 in reference Miwa et al. 
60
). From this observation, we 
hypothesized that Ra-223 as well as bisphosphonate cannot destroy cancer cells existing in 
the remote area from a bone matrix distantly although alpha particles from Ra-223 kill cancer 
cells near the bone matrix. However, since prostate cancer cells living in the remote area from 
the bone matrix continues still secreting PSA, PSA may be elevated. This speculation may 
explain the discrepancy between PSA and BSI/Alp (Border attack by Ra-223). Post hoc 
analysis of ALYSYMPCA trial showed that median overall survival was also longer in 
patients who received Ra-223 plus abiraterone, enzalutamide, or both than in those who did 
not receive these agents 61. Moreover, according to the result of ALSYMPCA trial, it is 
considered that it was the most effective to use Ra-223 for the patients with moderate bone 
metastases (Extent of disease score: 2 to 3 or 2-7% of BSI). When physicians use Ra-223 for 
bone metastasis, it will be necessary to evaluate the degree of bone metastasis exactly and 
consider concomitant drugs.  
 
Evaluation of Image 




A decline and an elevation of serum PSA value are the effective biomarker when 
physicians judge the regression and the recurrence of prostate cancer. However, they 
sometimes experience that a symptom of patients worsens and the results of the image are 
poor even if an absolute value of the PSA is low. Moreover, PSA value may not become the 
prognostic marker 62 63. Since advanced prostate cancer often metastasize to bone, it is 
extremely important to evaluate the change of bone metastasis. The extent of disease (EOD) 
on bone scintigraphy was used to stratify the level of bone metastasis 
64
. However, it was 
difficult to monitor EOD quantitatively. Therefore, the Prostate Cancer Clinical Trials 
Working Group 3 (PCWG3) recommends to use bone scintigraphy only for progression of 
bone metastasis 
65
. Recently, a computer-aided diagnosis system (CAD) on bone scintigraphy 
has been developed for improving the interpretations of bone scan images. CAD shows Bone 
Scan Index (BSI) which provides a quantitative measure of the percentage of the adult 
skeleton involved by bone metastases 
57, 66
. BSI on bone scintigraphy was a predictor of 
overall survival 
67-69
. Measurement of BSI revealed that PSA is not always correlated with the 
level of bone metastasis 
29
. PCWG3 also recommends computed tomography (CT) to 
evaluate lymph node metastases and visceral metastases 
65
. It is extremely important to 
evaluate not only the PSA value but also various images regularly and to treat for CRPC. 






When physicians choose the therapy for patients with CRPC, it is extremely important to 
judge comprehensively in consideration of (1) the effectiveness of therapeutic drugs based on 
evidence in Japan, (2) the PSA nadir level and the situation of the progress after CRPC, (3) 
treatment responsiveness for vintage and new hormonal therapy, (4) the evaluation with the 
image, (5) the adverse event by the treatment. 
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Fig. 1 The comparison of antiandrogen lines number in the clinical trial of new hormonal 
therapies between foreign countries and Japan. A. Clinical trial of abiraterone acetate after 
docetaxel treatment. B. Clinical trial of enzalutamide after docetaxel treatment. This figure 





Fig. 2 Rechallenge of hormonal therapy after chemotherapy. A. The case that enzalutamide 
(Enz) was successful later using docetaxel (DOC), dexamethasone (DEX), TAK-700 
(Orteronel, a CYP17A1 inhibitor like abiraterone acetate, was used in Phase II clinical study), 
Enz, and cabazitaxel (Cab) sequentially. B. The case that abiraterone was successful later 
using bicalutamide (Bic), flutamide (Flu), estramustine phosphate (EMT), ethinyl-estradiol 
(Ethinyl-E2), DOC, Enz, ITK-1 (peptide vaccine Phase III clinical study, DEX vs DEX + 
peptide vaccine) 
70
, and Cab sequentially.  
 
 




Fig. 3 Seesaw theory. A. Prostate cancer tissue, especially CRPC tissue is heterogeneous 
including androgen-hypersensitive cells and androgen-independent cells. Hormonal therapies 
can attack androgen-hypersensitive cells but not androgen-independent cells. Although 
chemotherapy can attack androgen-independent cells and androgen-hypersensitive cells, the 
effect of chemotherapy on androgen-hypersensitive cells is weak. B. 
Androgen-hypersensitive cells increase during chemotherapy. C. Androgen-independent cells 
increase during hormonal therapy. D. Androgen-hypersensitive cells increase during other 
chemotherapy again.  
 
 





Figure 1/The comparison of antiandrogen lines number in the clinical trial of new hormonal therapies 
between foreign countries and Japan. A. Clinical trial of abiraterone acetate after docetaxel treatment. B. 
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Mizokami et al. 22.  
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